REGENXBIO to Participate in Upcoming Investor Conferences
REGENXBIO to Participate in Upcoming Investor Conferences
ROCKVILLE, Md., May 10, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following upcoming investor conferences:
馬里蘭州羅克維爾，2024年5月10日 /PRNewswire/ — REGENXBIO Inc.（納斯達克股票代碼：RGNX）今天宣佈將參加以下即將舉行的投資者會議：
BofA Securities Health Care Conference 2024
Fireside Chat: Wednesday, May 15, 2024 at 2:20 p.m. ET
Location: Las Vegas, NV
美銀證券2024年醫療保健會議
爐邊聊天： 美國東部時間 2024 年 5 月 15 日星期三下午 2:20
地點： 內華達州拉斯維加斯
Stifel 2024 Tailoring Genes Genetic Medicines Forum
Fireside Chat: Tuesday, May 28, 2024 at 4:10 p.m. ET
Location: Virtual
Stifel 2024 定製基因遺傳藥物論壇
爐邊聊天： 美國東部時間 2024 年 5 月 28 日星期二下午 4:10
地點： 虛擬
A live webcast of the presentation at the BofA conference and fireside chat at the Stifel forum can be accessed in the Investors section of REGENXBIO's website at . An archived replay of the webcast will be available for approximately 30 days following the presentation.
可以在REGENXBIO網站的 “投資者” 欄目中觀看美銀會議演講的網絡直播和Stifel論壇的爐邊談話。網絡直播的存檔重播將在演示結束後的大約30天內提供。
ABOUT REGENXBIO Inc.
關於 REGENXBIO Inc.
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the development of AAV Therapeutics, an innovative class of gene therapy medicines. REGENXBIO is advancing a pipeline of AAV Therapeutics for retinal and rare diseases, including ABBV-RGX-314 for the treatment of wet AMD and diabetic retinopathy, being developed in collaboration with AbbVie, RGX-202 for the treatment of Duchenne and RGX-121 for the treatment of MPS II. Thousands of patients have been treated with REGENXBIO's AAV Therapeutic platform, including Novartis' ZOLGENSMA for children with spinal muscular atrophy. Designed to be one-time treatments, AAV Therapeutics have the potential to change the way healthcare is delivered for millions of people. For more information, please visit .
REGENXBIO是一家領先的臨床階段生物技術公司，致力於通過基因療法的治療潛力改善生活。自2009年成立以來，REGENXBIO率先開發了AAV Therapeutics，這是一種創新的基因治療藥物。REGENXBIO 正在推進用於視網膜和罕見疾病的 AAV 療法產品線，包括與艾伯維合作開發的用於治療溼性 AMD 和糖尿病視網膜病變的 ABBV-RGX-314、用於治療杜興氏的 RGX-202 和用於治療 MPS II 的 RGX-121。成千上萬的患者已經使用REGENXBIO的AAV治療平台接受了治療，其中包括諾華針對脊髓性肌萎縮症患兒的ZOLGENSMA。AAV Therapeutics設計爲一次性治療，有可能改變爲數百萬人提供醫療服務的方式。欲了解更多信息，請訪問。
Contacts:
聯繫人：
Dana Cormack
Corporate Communications
[email protected]
達娜·科馬克
企業傳播
[電子郵件保護]
Investors:
Chris Brinzey, ICR Westwicke
339-970-2843
[email protected]
投資者：
Chris Brinzey，ICR Westwicke
339-970-2843
[電子郵件保護]
SOURCE REGENXBIO Inc.
來源 REGENXBIO Inc.